Eli Lilly's Upcoming Earnings Report and the Significance of Retatrutide
Eli Lilly is set to report third-quarter earnings on October 29. While investors will closely watch sales performance for its diabetes and obesity drugs Mounjaro and Zepbound, attention remains focused on retatrutide—a promising experimental treatment for obesity with potential long-term growth implications. Retatrutide targets three hormone receptors involved in appetite regulation, blood sugar control, and metabolism. Clinical trials have shown impressive results: patients lost up to 28.3% of body weight over 80 weeks without diabetes, while those with type 2 diabetes saw an average loss of 20.8%. However, the drug has yet to demonstrate a reduction in major cardiovascular events. Eli Lilly plans to submit retatrutide for FDA approval by early 2027 and may position it as a complementary option alongside Zepbound rather than a direct replacement. The company's obesity treatment business is already growing rapidly; second-quarter revenue reached $22.97 billion, up 48% year over year.
Tickers: $LLY
Topics: Clinical Trials Mounjaro Obesity Drugs Pharmaceuticals Retatrutide Zepbound